Alpha2B and alpha2C agonists

Details for Australian Patent Application No. 2009244536 (hide)

Owner Allergan, Inc.

Inventors Li, Ling; Wang, Lilly; Takeuchi, Janet A.; Chow, Ken

Agent Davies Collison Cave

Pub. Number AU-A-2009244536

PCT Pub. Number WO2009/137340

Priority 61/050,367 05.05.08 US

Filing date 1 May 2009

Wipo publication date 12 November 2009

International Classifications

C07D 263/28 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

A61K 31/421 (2006.01) - 1,3-Oxazoles, e.g. pemoline, trimethadione

A61P 29/02 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

Event Publications

2 December 2010 PCT application entered the National Phase

  PCT publication WO2009/137340 Priority application(s): WO2009/137340

17 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009244538-Therapeutically useful substituted 1, 7-diphenyl-l, 2, 3, 5, 6, 7-hexahydropyrido [ 3, 2, 1-I J ] quinoline compounds

2009244535-Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives